ScoreWhy is Neurocrine Biosciences, Inc. ?
1
High Management Efficiency with a high ROE of 20.73%
2
Company has a low Debt to Equity ratio (avg) at times
3
Healthy long term growth as Net Sales has grown by an annual rate of 20.07% and Operating profit at 6.96%
4
Positive results in Jun 25
- OPERATING CASH FLOW(Y) Highest at USD 567.3 MM
- RAW MATERIAL COST(Y) Fallen by -1.04% (YoY)
- NET SALES(Q) Highest at USD 687.5 MM
5
With ROE of 13.90%, it has a expensive valuation with a 4.89 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 12.92%, its profits have fallen by -2.6%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Neurocrine Biosciences, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Neurocrine Biosciences, Inc. for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Neurocrine Biosciences, Inc.
22.94%
0.18
36.99%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
20.07%
EBIT Growth (5y)
6.96%
EBIT to Interest (avg)
16.61
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
0.84
Tax Ratio
34.41%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
30.41%
ROE (avg)
20.73%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
4.89
EV to EBIT
22.96
EV to EBITDA
21.72
EV to Capital Employed
7.03
EV to Sales
4.77
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
30.61%
ROE (Latest)
13.90%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 567.3 MM
RAW MATERIAL COST(Y)
Fallen by -1.04% (YoY
NET SALES(Q)
Highest at USD 687.5 MM
-4What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 1 times
DEBT-EQUITY RATIO
(HY)
Highest at -18.03 %
DEBTORS TURNOVER RATIO(HY)
Lowest at 4.72 times
Here's what is working for Neurocrine Biosciences, Inc.
Operating Cash Flow
Highest at USD 567.3 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 687.5 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Raw Material Cost
Fallen by -1.04% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Neurocrine Biosciences, Inc.
Inventory Turnover Ratio
Lowest at 1 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debt-Equity Ratio
Highest at -18.03 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Debtors Turnover Ratio
Lowest at 4.72 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
